Preclinical assessment of synergistic efficacy of MELK and CDK inhibitors in adrenocortical cancer

BACKGROUND: Adrenocortical cancer (ACC) is a rare and aggressive cancer with dismal 5-year survival due to a lack of effective treatments. We aimed to identify a new effective combination of drugs and investigated their synergistic efficacy in ACC preclinical models. METHODS: A quantitative high-thr...

Descripción completa

Detalles Bibliográficos
Autores principales: Laha, Dipranjan, Grant, Robert R.C., Mishra, Prachi, Boufraqech, Myriem, Shen, Min, Zhang, Ya-Qin, Hall, Matthew D., Quezado, Martha, De Melo, Michelly Sampaio, Del Rivero, Jaydira, Zeiger, Martha, Nilubol, Naris
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2022
Materias:
Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9502945/
https://www.ncbi.nlm.nih.gov/pubmed/36151566
http://dx.doi.org/10.1186/s13046-022-02464-5

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9502945/
https://www.ncbi.nlm.nih.gov/pubmed/36151566
http://dx.doi.org/10.1186/s13046-022-02464-5

Ejemplares similares